Optimizing further treatment choices in short-and long-term responders to first-line therapy for patients with advanced renal cell carcinoma

Expert Review of Anticancer Therapy

Volumn 12, Issue 8, 2012, Pages 1089-1096

  Procopio, Giuseppe ^a   Sabbatini, Roberto ^b   Porta, Camillo ^c   Verzoni, Elena ^a   Galligioni, Enzo ^d   Ortega, Cinzia ^e  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^d SANTA CHIARA HOSPITAL   (Italy)

^e Fondazione Del Piemonte per l'Oncologia   (Italy)

Author keywords

renal cell carcinoma; resistance; second and third line therapy; short and long term responders; sorafenib; targeted therapies; tyrosine kinase inhibitors

Indexed keywords

AXITINIB; CYTOKINE; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PAZOPANIB; PLACEBO; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR;

ADVANCED CANCER; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SURVIVAL; DRUG DOSE REDUCTION; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; HEART DISEASE; HEART INJURY; HEART MUSCLE INJURY; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LIFE SUSTAINING TREATMENT; LONG TERM CARE; METASTASIS; NONHUMAN; OVERALL SURVIVAL; PATIENT CARE; PREDICTIVE VALUE; PRIMARY HEALTH CARE; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME;

AGE FACTORS; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; HUMANS; KIDNEY NEOPLASMS; PROTEIN KINASE INHIBITORS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84867064327     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.12.76     Document Type: Review

References (51)

1. Hutson TE. Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence. Oncologist 16(Suppl. 2), 14-22 (2011).
2. Escudier B. Sorafenib for the management of advanced renal cell carcinoma. Expert Rev. Anticancer Ther. 11(6), 825-836 (2011).
3. Porta C, Szczylik C, Escudier B. Combination or sequencing strategies to improve the outcome of metastatic renal cell carcinoma patients: a critical review. Crit. Rev. Oncol. Hematol. 82(3), 323-337 (2012).
4. Hutson TE, Bukowski RM, Cowey CL, Figlin R, Escudier B, Sternberg CN. Sequential use of targeted agents in the treatment of renal cell carcinoma. Crit. Rev. Oncol. Hematol. 77(1), 48-62 (2011).
5. Heng DY, Mackenzie MJ, Vaishampayan UN et al. Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy. Ann. Oncol. 23(6), 1549-1555 (2012).
6. Porta C, Tortora G, Linassier C et al. Maximising the duration of disease control in metastatic renal cell carcinoma with targeted agents: an expert agreement. Med. Oncol. doi:10.1007/s12032-011-0016-8 (2011) (Epub ahead of print).
7. Knox JJ. Progression-free survival as endpoint in metastatic RCC?. Lancet 372(9637), 427-429 (2008).
8. McCain JA Jr. The ongoing evolution of endpoints in oncology. Clin. Briefs 19(5 Suppl. 1), 3-11 (2010).
9. Rini BI. Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions. Clin. Cancer Res. 13(4), 1098-1106 (2007).
10. Escudier B, Szczylik C, Eisen T et al. Randomized Phase III trial of the multikinase inhibitor BAY 43-9006 in patients with advanced renal cell carcinoma. Eur. J. Cancer 3, 226 (2005).
11. Gossage L, Eisen T. Targeting multiple kinase pathways: a change in paradigm. Clin. Cancer Res. 16(7), 1973-1978 (2010).
12. Mekhail TM, Abou-Jawde RM, Boumerhi G et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J. Clin. Oncol. 23(4), 832-841 (2005).
13. Heng DY, Xie W, Regan MM et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J. Clin. Oncol. 27(34), 5794-5799 (2009).
14. Gordan JD, Lal P, Dondeti VR et al. HIF-a effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell 14(6), 435-446 (2008).
15. Smith AD, Shah SN, Rini BI, Lieber ML, Remer EM. Utilizing pre-therapy clinical schema and initial CT changes to predict progression-free survival in patients with metastatic renal cell carcinoma on VEGF-targeted therapy: a preliminary analysis. Urol. Oncol. doi:10.1016/j. urolonc.2011.08.010 (2011) (Epub ahead of print).
16. Procopio G. Role of sorafenib in renal cell carcinoma: focus on elderly patients. Expert Rev. Anticancer Ther. 11(11), 1689-1692 (2011).
17. Schmidinger M, Zielinski CC, Vogl UM et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 26(32), 5204-5212 (2008).
18. Bellmunt J, Nègrier S, Escudier B, Awada A, Aapro M; SIOG Taskforce. The medical treatment of metastatic renal cell cancer in the elderly: position paper of a SIOG Taskforce. Crit. Rev. Oncol. Hematol. 69(1), 64-72 (2009).
19. Josephs D, Hutson TE, Cowey CL et al. Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis. BJU Int. 108(8), 1279-1283 (2011).
20. Massard C, Zonierek J, Gross-Goupil M, Fizazi K, Szczylik C, Escudier B. Incidence of brain metastases in renal cell carcinoma treated with sorafenib. Ann. Oncol. 21(5), 1027-1031 (2010).
21. Larkin J, Swanton C, Pickering L. Optimizing treatment of metastatic renal cell carcinoma by changing mechanism of action. Expert Rev. Anticancer Ther. 11(4), 639-649 (2011).
22. Furge KA, MacKeigan JP, Teh BT. Kinase targets in renal-cell carcinomas: reassessing the old and discovering the new. Lancet Oncol. 11(6), 571-578 (2010).
23. Ravaud A, Digue L, Trufflandier N, Smith D. VEGFR TKI 'resistance' or transient clinical insensitivity to VEGFR TKI in metastatic renal cell carcinoma. Ann. Oncol. 21(2), 431-432 (2010).
24. Hutson TE. Emerging applications of established VEGF and mTOR therapy for metastatic RCC: therapy re-challenge. Presented at: Eighth International Kidney Cancer Symposium. Chicago, IL, USA, 25-26 September 2009.
25. Rini BI, Hutson TE, Elson P et al. Clinical activity of sunitinib rechallenge in metastatic renal cell carcinoma. Presented at: 2010 Genitourinary Cancers Symposium. San Francisco, CA, USA, 5-7 March 2010 (Abstract 319).
26. Zama IN, Hutson TE, Elson P et al. Sunitinib rechallenge in metastatic renal cell carcinoma patients. Cancer 116(23), 5400-5406 (2010).
27. Nozawa M, Matsumura N, Yasuda M. Activity of retreatment with sorafenib for metastatic renal cell carcinoma. J. Clin. Oncol. 29(Suppl. 7), Abstract 404 (2011).
28. Zhang L, Bhasin M, Schor-Bardach R et al. Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression. PLoS ONE 6(4), e19144 (2011).
29. Naito S, Tsukamoto T, Murai M, Fukino K, Akaza H. Overall survival and good tolerability of long-term use of sorafenib after cytokine treatment: final results of a Phase II trial of sorafenib in Japanese patients with metastatic renal cell carcinoma. BJU Int. 108(11), 1813-1819 (2011).
30. Gruenwald V, Seidel C, Fenner M et al. Antitumor activity of tyrosine kinase inhibitors (TKI) after failure of RAD001 in metastatic renal cell carcinoma (mRCC). Presented at: Genitoururinary Cancers Symposium. San Francisco, CA, USA, 5-7 March 2010 (Abstract 414).
31. Rini BI, Szczylik C, Tannir NM et al. AMG 386 in combination with sorafenib in patients (pts) with metastatic renal cell cancer (mRCC): a randomized, doubleblind, placebo-controlled, Phase II study. J. Clin. Oncol. (Suppl. 7), Abstract 309 (2011).
32. Heng DY, MacKenzie MJ, Vaishampayan UN et al. International mRCC Database Consortium. Primary anti-VEGF-refractory metastatic renal cell carcinoma (mRCC): clinical characteristics, risk factors, and subsequent therapy. J. Clin. Oncol. 29(Suppl. 7), Abstract 305 (2011).
33. Di Lorenzo G, Buonerba C, Federico P et al. Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma. Eur. Urol. 58(6), 906-911 (2010).
34. Vickers MM, Choueiri TK, Rogers M et al. Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy. Urology 76(2), 430-434 (2010).
35. Al-Marrawi MY, Rini BI, Harshman LC et al. The association of clinical outcome to front-line VEGF-targeted therapy with clinical outcome to second-line VEGFtargeted therapy in metastatic renal cell carcinoma (mRCC) patients (Pts) J. Clin. Oncol. 29(Suppl.), Abstract 4555 (2011).
36. Albiges L, Iacovelli R, Porta C et al. Prognosis of patients with metastatic renal cell carcinoma with primary resistance to sunitinib: is there a good treatment?. Eur. J. Cancer 47 (Suppl. 1), 545 Abstract 7143 (2011).
37. Gore ME, Larkin JM. Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies. Br. J. Cancer 104(3), 399-406 (2011).
38. Escudier B, Ravaud A, Oudard S et al. Phase-3 randomised trial of everolimus (RAD001) vs placebo in metastatic renal cell carcinoma. Ann. Oncol. 19(Suppl. 8), Abstract 72O (2008).
39. Motzer RJ, Escudier B, Oudard S et al.; RECORD-1 Study Group. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 116(18), 4256-4265 (2010).
40. Motzer RJ, Hutson TE, Tomczak P et al. Overall survival and updated results for sunitinib compared with interferon a in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27(22), 3584-3590 (2009).
41. Sternberg CN, Davis ID, Mardiak J et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized Phase III trial. J. Clin. Oncol. 28(6), 1061-1068 (2010).
42. Sternberg CN, Hawkins R, Szczylik C et al. Randomized, double-blind Phase III study of pazopanib in patients with advanced metastatic renal cell carcinoma (mRCC): final overall survival (OS) results. Ann. Oncol. 21(Suppl. 8), Abstract LBA22 (2010).
43. Rini BI, Escudier B, Tomczak P et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised Phase 3 trial. Lancet 378(9807), 1931-1939 (2011).
44. Beck J, Procopio G, Bajetta E et al. Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings. Ann. Oncol. 22(8), 1812-1823 (2011).
45. Sadeghi S, Albiges L, Wood LS et al. Cessation of vascular endothelial growth factor-targeted therapy in patients with metastatic renal cell carcinoma: feasibility and clinical outcome. Cancer 118(13), 3277-3282 (2012).
46. Rini BI, Flaherty K. Clinical effect and future considerations for molecularlytargeted therapy in renal cell carcinoma. Urol. Oncol. 26(5), 543-549 (2008).
47. Porta C, Paglino C, Imarisio I. Sequencing tyrosine kinase inhibitors or immediately switching to mTOR inhibitors in advanced kidney cancer: a critical review. Eur. J. Med. Clin. Oncol. 2, 67-72 (2011).
48. Busch J, Seidel C, Kempkensteffen C et al. Sequence therapy in patients with metastatic renal cell carcinoma: comparison of common targeted treatment options following failure of receptor tyrosine kinase inhibitors. Eur. Urol. 60(6), 1163-1170 (2011).
49. Porta C, Bellmunt J, Eisen T, Szczylik C, Mulders P. Treating the individual: the need for a patient-focused approach to the management of renal cell carcinoma. Cancer Treat. Rev. 36(1), 16-23 (2010).
50. van der Veldt AA, Eechoute K, Gelderblom H et al. Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib. Clin. Cancer Res. 17(3), 620-629 (2011).
51. Garcia-Donas J, Esteban E, Leandro-García LJ et al. Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. Lancet Oncol. 12(12), 1143-1150 (2011).